[1]Manning DS,Afdhal NH.Diagnosis and quantitation offibrosis[J].Gastroenterology,2008,134(6):1670-1681.
|
[2]Bedossa P,Dargere D,Paradis V.Sampling variability ofliver fibrosis in chronic hepatitis C[J].Hepatology,2003,38(6):1449-1457.
|
[3]Gressner OA,Weiskirchen R,Gressner AM.Biomarkersof hepatic fibrosis,fibrogenesis and genetic pre-disposition pending between fiction and reality[J].J CellMol Med,2007,11(5):1031-1051.
|
[4]Dufour DR.Assessment of liver fibrosis:can serumbecome the sample of choice?[J].Clin Chem,2005,51(10):1763-1764.
|
[5]Tarcin O,Gedik N,Karakoyun B,et al.Serum prolidaseand IGF-1 as non-invasive markers of hepatic fibrosisduring four different periods after bile-ductligation inrats[J].Dig Dis Sci,2008,53(7):1938-1945.
|
[6]Kurien BT,Patel NC,Porter AC,et al.Prolidase deficiencyand the biochemical assays used in its diagnosis[J].AnalBiochem,2006,349(2):165-175.
|
[7]Kayadibi H,Gultepe M,Yasar B,et al.Diagnostic valueof serum prolidase enzyme activity to predict the liverhistological lesions in non-alcoholic fatty liver disease:Asurrogate marker to distinguish steatohepatitis fromsimple steatosis[J].Dig Dis Sci,2009,54(8):1764-1771.
|
[8]Friedman SL.Molecular regulation of hepatic fibrosis,an integrated cellular response to tissue injury[J].J BiolChem,2000,275(4):2247-2250.
|
[9]Zeremski M,Dimova R,Brown Q,et al.Peripheral CXCR3-associated chemokines as biomarkers of fibrosis inchronic hepatitis C virus Infection[J].J Infect Dis,2009,200(11):1774-1780.
|
[10]Zeremski M,Petrovic LM,Chiriboga L,et al.Intrahepaticlevels of CXCR3-associated chemokines correlate withliver inflammation and fibrosis in chronic hepatitis C[J].Hepatology,2008,48(5):1440-1414.
|
[11]Shaheen AA,Myers RP.Diagnostic accuracy of theaspartate aminotransferase-to-platelet ratio index for theprediction of hepatitis C-related fibrosis:a systematicreview[J].Hepatol,2007,46:912-921.
|
[12]Poynard T,McHutchison J,Manns M,et al.Biochemicalsurrogate markers of liver fibrosis and activity in arandomized trial of peginterferon alfa-2b and ribavirin[J].Hepatology,2003,38(2):481-492.
|
[13]Poynard T,Munteanu M,Imbert-Bismut F,et al.Prospe-ctive analysis of discordant results between biochemicalmarkers and biopsy in patients with chronic hepatitis C[J].Clinical Chemistry,2004,50(8):1344-1355.
|
[14]Romero Gómez M,Ramírez Martín del Campo M,OteroMA,et al.Comparative study of two models that usebiochemical parameters for the noninvasive diagnosisof fibrosis in patients with hepatitis C[J].Med Clin,2005,124(20):761-764.
|
[15]Marín-Gabriel JC,Solís-Herruzo JA.Noninvasiveassessment of liver fibrosis.Serum markers andtransient elastography(FibroScan)[J].Rev Esp EnfermDig,2009,101(11):787-799.
|
[16]Poon TC,Hui AY,Chan HL,et al.Prediction of liverfibrosis and cirrhosis in chronic hepatitis B infection byserum proteomic FIngerprinting:a pilot study[J].ClinChem,2005,51(2):328-335.
|
[17]Morra R,Munteanu M,Bedossa P,et al.Diagnostic value ofserum protein profiling by SELDI-TOF ProteinChip comparedwith a biochemical marker,FibroTest,for the diagnosis ofadvanced fibrosis in patients with chronic hepatitis C[J].Aliment Pharmacol Ther,2007,26(6):847-858.
|
[18]Callewaert N,Vlierberghe HV,Hecke AV,et al.Noninvasive diagnosis of liver cirrhosis using DNAsequencer-based total serum protein glycomics[J].NatMed,2004,10(4):429-434.
|
[19]Chen CY,Schmilovitz-Weiss H,Liu XE,et al.Serumprotein N-Glycans Profiling for the discovery of potentialbiomarkers for nonalcoholic steatohepatitis[J].JProteome Res,2009,8(2):463-470.
|
[20]Lim AK,Taylor-Robinson SD,Patel N,et al.Hepatic veintransit times using a microbubble agent can predictdisease severity non-invasively in patients with hepatitisC[J].Gut,2005,54(1):128-133.
|
[21]Janssens F,de Suray N,Piessevaux H,et al.Cantran-sient elastography replace liver histology fordetermination of advanced fibrosis in alcoholic patients:A real-life study[J].Clin Gastroenterol,2010[Epubahead of print].
|
[22]Castera L.Transient elastography and other noninvasivetests to assess hepatic fibrosis in patients with viralhepatitis[J].J Viral Hepat,2009,16(5):300-314.
|
[23]Bonnard P,SombiéR,Lescure FX,et al.Comparison ofelastography,serum marker scores,and histology for theassessment of liver fibrosis in hepatitis B virus(HBV)-infected patients in Burkina Faso[J].Trop Med Hyg,2010,82(3):454-458.
|
[24]Huwart L,Sempoux C,Vicaut E,et al.Magnetic resonan-ce elastography for the noninvasive staging of liverfibrosis[J].Gastroenterology,2008,135(1):32-40.
|
[25]RouvièreO,Yin M,Dresner MA,et al.MR elastographyof the liver:preliminary results[J].Radiology,2006,240(2):440-448.
|
[26]Yin M,Talwalkar JA,Glaser KJ,et al.Assessment ofhepatic fibrosis with magnetic resonance elastography[J].Clin Gastroenterol Hepatol,2007,5(10):1207-1213.
|
[27]Faria SC,Ganesan K,Mwangi DI,et al.MR Imagingof Liver Fibrosis:Current State of the Art[J].RadioGraphics,2009,29(6):1615-1635.
|
[28]Lewin M,Poujol-Robert A,Boelle PY,et al.Diffusion-weighted magnetic resonance imaging for theassessment of fibrosis in chronic hepatitis C[J].Hepatology,2007,46(3):658-665.
|
[29]Taouli B,Koh DM.Diffusion-weighted MR Imaging of theLiver[J].Radiology,2010,254(1):47-66.
|
[30]Taouli B,Tolia AJ,Losada M,et al.Diffusion-weighted MRIfor quantifcation of liver fbrosis:preliminary experience[J].AJR Am J Roentgenol,2007,189(4):799-806.
|
[31]Boulanger Y,Amara M,Lepanto L,et al.Diffusion-weighted MR imaging of the liver of hepatitis Cpatients[J].NMR Biomed,2003,16(3):132-136.
|
[1] | Yu WANG, Min WANG, Guanhua ZHANG, Fuliang HE, Xiaojuan OU, Jidong JIA. Clinical diagnosis, staging, and therapeutic principles of liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 17-21. doi: 10.3969/j.issn.1001-5256.2021.01.004 |
[2] | Zhao WenShan, Xie Wen. Clinical assessment of the reversal of liver cirrhosis: “Point of return”[J]. Journal of Clinical Hepatology, 2019, 35(4): 724-727. doi: 10.3969/j.issn.1001-5256.2019.04.005 |
[3] | Chen YongPeng, Liang XieEr. Radiological evaluation of the reversal of liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(4): 720-723. doi: 10.3969/j.issn.1001-5256.2019.04.004 |
[4] | Liu TianHui. Serological assessment of the reversal of liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(4): 714-719. doi: 10.3969/j.issn.1001-5256.2019.04.003 |
[5] | Tang ChengWei. Work-up for diagnosis and treatment of liver cirrhosis: convention and development[J]. Journal of Clinical Hepatology, 2016, 32(2): 201-202. doi: 10.3969/j.issn.1001-5256.2016.02.001 |
[6] | Han Tao. Acute-on-chronic liver failure due to bacterial infection in liver cirrhosis: causes and management[J]. Journal of Clinical Hepatology, 2015, 31(9): 1415-1417. doi: 10.3969/j.issn.1001-5256.2015.09.012 |
[7] | Zhang JingWen, Shi YongQuan, Han Ying. Progress in treatment of liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 465-468. doi: 10.3969/j.issn.1001-5256.2015.03.037 |
[8] | Xie WeiFen, Ceng Xin. Controversial problems in management of cirrhotic ascites[J]. Journal of Clinical Hepatology, 2014, 30(7): 601-603. doi: 10.3969/j.issn.1001-5256.2014.07.006 |
[9] | Lu LunGen, Li ZhengHong. Diagnosis and assessment of liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(7): 577-579. doi: 10.3969/j.issn.1001-5256.2014.07.001 |
[10] | Wu JianJin, Yao DingKang. Recent advances in understanding the relations between liver cirrhosis and sleep disorders[J]. Journal of Clinical Hepatology, 2013, 29(5): 397-400. |
[11] | Lu LunGen, Li ZhengHong. Recent research on liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(5): 321-323. |
[12] | Wei SiChen, Zheng GuoQi. Role of adipokine in the pathogenesis of cirrhosis of the liver[J]. Journal of Clinical Hepatology, 2012, 28(1): 78-81. |
[13] | Chen Jing, Liu XiaoYan, Hu JinHua, Duan XueZhang, He WeiPing, Wang HuiFen, Xin ShaoJie. Clinical analysis of 24 cases of congenital hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1041-1043. |
[14] | Zhong Wei, Xie WeiFen. New strategy for the treatment of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 233-235. |
[15] | Qiu Ling, Hu YuLin. Recent status and prospect of ascites treatment in cirrhosis patients[J]. Journal of Clinical Hepatology, 2010, 26(6): 663-665. |
[16] | Wang CaiSheng. Progress of diagnosis in liver fibrosis[J]. Journal of Clinical Hepatology, 2010, 26(6): 666-668. |
[18] | Li XiaoFeng, Yang XiaoMing, Zhu JianMin, Wang JiXian. The relation between cirrhosis and GERD[J]. Journal of Clinical Hepatology, 2000, 16(4): 243-244. |
[19] | Shang Jia, Wang XiuQi, Jin Xiu, Li YuKui, Li XiuLing. The Targets Hyperfibrinolysis Influence the Prognosis in Cirrhosis Patients[J]. Journal of Clinical Hepatology, 2000, 16(1): 35-36. |